Beste apotheek van Nederland

erection” versus one placebo treated subject 296 . Erectile activity was reported in 63 percent
(12/19) of Melanotan II injections compared with 2 percent (1/21) of placebo injections.
PT-141 versus placebo. One small trial that enrolled 25 subjects with moderate to severe ED
who had an inadequate response to sildenafil compared the efficacy and harms of PT–141 (SC)
to placebo 298 . PT-141 was administered in doses of 4 or 6 mg, utilizing a placebo-controlled
three-way crossover design 298 . Patients were kept under observation until 24 hours after the dose
administration.
Harms. Men who were administered PT-141 reported an increased frequency of nausea (4
mg: 24 percent versus 6 mg: 36 percent versus placebo: 0 percent) and headache (4 mg: 36
percent versus 6 mg: 27 percent versus placebo: 0 percent) compared with placebo.
Efficacy. Clinically and statistically significant erectile response (assessed by RigiScan) in
the presence of visual sexual stimulation was observed following the administration of single
dose of 4 or 6 mg PT-141, relative to placebo. A greater than two-fold increase in the duration of
base rigidity ≥ 60 percent, compared with placebo, was reported in 82 percent of subjects
receiving the 4 mg dose and 84 percent of patients receiving the 6 mg dose.
Apomorphine versus placebo. One small trial enrolling 12 subjects with coital erectile
failure of at least 6 months compared apomorphine (SC) to placebo. 297
Harms. Eight subjects reported side effects, including yawning, drowsiness and nausea. Two
participants experienced extreme nausea and hypotension, with one transiently losing
consciousness after the 1.0 mg apomorphine dose.
Efficacy. Eleven out of the 12 subjects exceeded a change of 1cm in circumference after
injection).
Quantitative Synthesis
No meta-analysis was performed due to the clinical heterogeneity with regard to intervention
types.
82